Christopher J. Senner serves as the Executive Vice President and Chief Financial Officer at Exelixis, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of new medicines to treat cancer. In his role, Senner is responsible for overseeing the financial strategy and operations of the company, ensuring its fiscal health and supporting its growth objectives. His leadership has been instrumental in navigating the complex financial landscape of the biopharmaceutical industry, contributing to Exelixis' success in bringing innovative cancer treatments to market. Before joining Exelixis, Senner held several high-level financial positions at other notable companies. He previously served as the Chief Financial Officer at Aimmune Therapeutics, where he played a key role in the company's successful initial public offering and subsequent growth. Prior to Aimmune, Senner worked at Onyx Pharmaceuticals, where he helped guide the company through its acquisition by Amgen. His extensive experience in the biopharmaceutical sector, coupled with his strategic financial acumen, has made him a valuable asset to Exelixis and its mission to advance cancer care. Senner's achievements in the industry are marked by his ability to drive financial performance while supporting the development of groundbreaking therapies. At Exelixis, he has been pivotal in managing the company's resources to fund research and development initiatives, as well as in securing partnerships and collaborations that enhance the company's pipeline. His strategic vision and dedication to the company's goals have solidified his reputation as a respected leader in the biopharmaceutical field.